Xiaodong Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaodong Zhu has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Chen Long
Department of Therapeutic Radiology, Guangxi Autonomous Regional Cancer Hospital & Cancer Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China
1 shared publication- Chunmei Bai
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
1 shared publication - Jifeng Feng
Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China
1 shared publication - Junbao Wei
Department of Therapeutic Radiology
1 shared publication - Kai Xue
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, School of Medicine Shanghai Jiao Tong University Shanghai China
1 shared publication - Kunyu Yang
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication
Latest Publications
- Open Access
- 1 October 2021
- Published by Elsevier in European Journal of Cancer
- Vol. 156, 35-45
First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial
- 1 October 2021
- Published by Elsevier in European Journal of Cancer
- Vol. 156, 35-45
Open AccessFirst-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial
- 1 January 2016
- Published by Elsevier in Oral Oncology
- Vol. 52, 11-17
Comparison of (18)F-FDG PET/CT, MRI and SPECT in the diagnosis of local residual/recurrent nasopharyngeal carcinoma: A meta-analysis
- 1 January 2016
- Published by Elsevier in Oral Oncology
- Vol. 52, 11-17
Comparison of (18)F-FDG PET/CT, MRI and SPECT in the diagnosis of local residual/recurrent nasopharyngeal carcinoma: A meta-analysis
- Open Access
- 24 November 2015
- Published by S. Karger AG in Breast Care
- Vol. 10 (6) , 413-416
Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-Analysis
Background: The aim of this study was to compare the efficacy of breast conservation surgery (BCS) followed by radiotherapy (RT) in triple negative breast cancer (TNBC) versus non-TNBC. Methods: We searched the MEDLINE and EMBASE databases from inception through March 31, 2014, using search terms related to TNBC, BCS, and RT. Studies comparing the efficacy of BCS followed by RT in TNBC versus non-TNBC were reviewed. Results: 5 studies including 2,922 non-TNBC and 510 TNBC cases were selected. The overall quality of included studies was deemed moderate to high. Compared with non-TNBC, the pooled relative risk of 5-year local relapse-free survival was 1.315 (95% confidence interval (CI) 0.967-1.789; p = 0.008) for TNBC, and that of 5-year overall survival, regional relapse-free survival, and distant metastasis-free survival was 1.929 (95% CI 1.392-2.674; p = 0.000), 3.052 (95% CI 1.629-5.715; p = 0.000), and 2.407 (95% CI 1.910-3.034; p = 0.000), respectively. Conclusion: The local control rate of TNBC treated with BCS plus RT is similar to that of non-TNBC.
- 24 November 2015
- Published by S. Karger AG in Breast Care
- Vol. 10 (6) , 413-416
Open AccessTriple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-Analysis
Background: The aim of this study was to compare the efficacy of breast conservation surgery (BCS) followed by radiotherapy (RT) in triple negative breast cancer (TNBC) versus non-TNBC. Methods: We searched the MEDLINE and EMBASE databases from inception through March 31, 2014, using search terms related to TNBC, BCS, and RT. Studies comparing the efficacy of BCS followed by RT in TNBC versus non-TNBC were reviewed. Results: 5 studies including 2,922 non-TNBC and 510 TNBC cases were selected. The overall quality of included studies was deemed moderate to high. Compared with non-TNBC, the pooled relative risk of 5-year local relapse-free survival was 1.315 (95% confidence interval (CI) 0.967-1.789; p = 0.008) for TNBC, and that of 5-year overall survival, regional relapse-free survival, and distant metastasis-free survival was 1.929 (95% CI 1.392-2.674; p = 0.000), 3.052 (95% CI 1.629-5.715; p = 0.000), and 2.407 (95% CI 1.910-3.034; p = 0.000), respectively. Conclusion: The local control rate of TNBC treated with BCS plus RT is similar to that of non-TNBC.
- 20 October 2014
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 127 (20) , 3638-3644
Tea drinking and risk of pancreatic cancer
Background Epidemiologic studies have reported inconsistent results regarding tea consumption and the risk of pancreatic cancer. This study aimed to investigate whether tea consumption is related to the risk of pancreatic cancer. Methods We searched Medline, EMBASE, ISI Web of Science, and the Cochrane library for studies published up to November 2013. We used a meta-analytic approach to estimate overall odds ratio (OR) and 95% confidence interval (CI) for the highest versus the lowest tea consumption categories. Results The summary OR for high versus no/almost never tea drinkers was 1.04 (95% CI: 0.91–1.20), with no significant heterogeneity across studies (P=0.751; I2=0.0%). The OR was 0.99 (95% CI: 0.77–1.28) in males and 1.01 (95% CI: 0.79–1.29) in females. The OR was 1.07 (95% CI: 0.85–1.34) in Asian studies, 1.05 (95% CI: 0.84–1.31) in European studies, and 0.98 (95% CI: 0.72–1.34) in the US studies. The OR was 0.87 (95% CI: 0.69–1.10) without adjustment for a history of diabetes and 1.16 (95% CI: 0.97–0.39) after adjustment for a history of diabetes. The OR was 0.90 (95% CI: 0.72–1.12) without adjustment for alcohol drinking and 1.16 (95% CI: 0.96–1.39) after adjustment for alcohol drinking. The OR was 0.97 (95% CI: 0.76–1.25) without adjustment for BMI and 1.07 (95% CI: 0.87–1.31) after adjustment for BMI. Conclusion This systematic meta-analysis of cohort studies dose not provide quantitative evidence that tea consumption is appreciably related to the risk of pancreatic cancer, even at high doses.
- 20 October 2014
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 127 (20) , 3638-3644
Tea drinking and risk of pancreatic cancer
Background Epidemiologic studies have reported inconsistent results regarding tea consumption and the risk of pancreatic cancer. This study aimed to investigate whether tea consumption is related to the risk of pancreatic cancer. Methods We searched Medline, EMBASE, ISI Web of Science, and the Cochrane library for studies published up to November 2013. We used a meta-analytic approach to estimate overall odds ratio (OR) and 95% confidence interval (CI) for the highest versus the lowest tea consumption categories. Results The summary OR for high versus no/almost never tea drinkers was 1.04 (95% CI: 0.91–1.20), with no significant heterogeneity across studies (P=0.751; I2=0.0%). The OR was 0.99 (95% CI: 0.77–1.28) in males and 1.01 (95% CI: 0.79–1.29) in females. The OR was 1.07 (95% CI: 0.85–1.34) in Asian studies, 1.05 (95% CI: 0.84–1.31) in European studies, and 0.98 (95% CI: 0.72–1.34) in the US studies. The OR was 0.87 (95% CI: 0.69–1.10) without adjustment for a history of diabetes and 1.16 (95% CI: 0.97–0.39) after adjustment for a history of diabetes. The OR was 0.90 (95% CI: 0.72–1.12) without adjustment for alcohol drinking and 1.16 (95% CI: 0.96–1.39) after adjustment for alcohol drinking. The OR was 0.97 (95% CI: 0.76–1.25) without adjustment for BMI and 1.07 (95% CI: 0.87–1.31) after adjustment for BMI. Conclusion This systematic meta-analysis of cohort studies dose not provide quantitative evidence that tea consumption is appreciably related to the risk of pancreatic cancer, even at high doses.